Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial

被引：0
|
作者：
Jin, Shui-Ling
Qiao, Shishi
Li, Ren-Feng
Zhang, Weijie
He, Wei
Su, Chang
Li, Lu-Hao
Pan, Jie
Guo, Wen-Zhi
Zong, Hong
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.3_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [31] Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wan-Rui
    Li, Xiaofen
    Tian, Bole
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial
    Zhou Jun
    Gong Jifang
    Cao Yanshuo
    Peng Zhi
    Yuan Jiajia
    Wang Xicheng
    Lu Ming
    Shen Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [33] Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer
    Li, Huikai
    Liu, Yang
    Zhang, Xihao
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55
  • [34] Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
    Zhang, T.
    Yu, D.
    Wang, J.
    Liu, J.
    Ma, H.
    Lin, Z.
    Jin, M.
    Zhang, J.
    Zhao, L.
    Liu, H.
    Hu, J.
    Zhang, Q.
    ANNALS OF ONCOLOGY, 2021, 32 : S1057 - S1058
  • [35] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
  • [37] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
  • [38] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [39] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [40] The overall survival data of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase II trial
    Wang, Z.
    Chen, L.
    Fan, L.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
12345